Nuformix hoping to "initiate discussions with major pharma" in 2023

ADVERTISEMENT

Click to copy

Press release content from News Direct Corporation. The AP news staff was not involved in its creation.

Click to copy

Related topics

Nuformix hoping to “initiate discussions with major pharma” in 2023

PRESS RELEASE: Paid content from News Direct Corporation

Press release content from News Direct Corporation. The AP news staff was not involved in its creation.

December 20, 2022 GMT

None

None

--News Direct--

Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive shortly after releasing an update on the company’s NXP004 programme, aimed at developing novel forms of AstraZeneca’s Olaparib (Lynparza) cancer drug. Gooding reveals what investors can expect from Nuformix in 2023, saying that his aspiration is for data from the NXP002 programme to be supportive of the company “initiating discussions with major pharma.”

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/nuformix-hoping-to-initiate-discussions-with-major-pharma-in-2023-475195778